CANCER FUND I invests in ultra high-risk, early-stage companies. Returns on some early stage companies can be significant, but there is no assurance CANCER FUND I will realize those returns. In fact, most of these early-stage companies fail and result in a total loss of their investors capital. Investors who cannot afford to lose their entire investment should not invest in CANCER FUND I. The primary investment objective of CANCER FUND I is impact, not financial returns.

Further, CANCER FUND and CANCER FUND I do not make investment recommendations or provide financial advice or advisement. We encourage you to speak with your financial advisor to determine what level of investment makes sense for you, if any at all. If you’d like, we’re happy to discuss the CANCER FUND opportunity with your financial advisor.

You can start by visiting www.cancerfund.com/invest and choosing the active investment opportunities that interest you.

CANCER FUND is a community of impact investors and acts as Manager of CANCER FUND I, LLC and other investment vehicles developed by CANCER FUND. CANCER FUND is owned and operated by CXO Advisors & Management, LLC. Accordingly, CANCER FUND is CXO Advisors & Management, LLC doing business as CANCER FUND.

Money committed by investors are invested into specific private funds, like CANCER FUND I, LLC with specific investment objectives. They are not invested in CXO Advisors & Management, LLC doing business as CANCER FUND.

CANCER FUND invests in early stage companies in three broad areas of focus:

1. Therapies and Management
2. Diagnostics & Monitoring
3. Preventions & Enabling Technologies

We invest in innovations to benefit four different groups of stakeholders:

1. Patients & Families
2. Medical Professionals and Caregivers
3. At Risk Populations
4. Payers & Policy Makers

We invest in the gap that is too late for research grants but too early for most venture capitalists. We focus on Pre-Seed, Seed, Seed+, and Series A funding rounds.

CANCER FUND I focuses on early-stage companies that can be difficult to identify. Sometimes companies find us, and sometimes we find them through our research and scouting efforts. We currently have identified nearly 600 innovative cancer companies seeking more than $2B in funding, and that list is constantly expanding.

Once a company has been identified, it is reviewed by CANCER FUND’s Pre-Screening teams for fit with our impact and investment criteria. Select companies are introduced to the public and our community through (virtual) Screening Committee. This is an opportunity for our community to participate in selecting which innovations we consider for investment.

If the Screening Committee recommends a company for further consideration, a due diligence evaluation is completed by the CANCER FUND Evaluation Committee, which may recommend investment be made. The CANCER FUND I Investment Committee makes all final investment decisions and manages the investment portfolio.

CANCER FUND completed its first investment in February 2021 and are currently evaluating companies for our next investment. 

You can review the companies in our portfolio by clicking HERE.